284 related articles for article (PubMed ID: 30627867)
1. Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis.
Scolari IR; Páez PL; Sánchez-Borzone ME; Granero GE
AAPS PharmSciTech; 2019 Jan; 20(2):67. PubMed ID: 30627867
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Toxicity, Lung Distribution, and Cellular Uptake of Rifampicin and Ascorbic Acid-Loaded Alginate Nanoparticles as Therapeutic Treatment of Lung Intracellular Infections.
Scolari IR; Volpini X; Fanani ML; La Cruz-Thea B; Natali L; Musri MM; Granero GE
Mol Pharm; 2021 Mar; 18(3):807-821. PubMed ID: 33356316
[TBL] [Abstract][Full Text] [Related]
3. Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design.
Petkar KC; Chavhan S; Kunda N; Saleem I; Somavarapu S; Taylor KMG; Sawant KK
AAPS PharmSciTech; 2018 May; 19(4):1758-1772. PubMed ID: 29589222
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin loaded in alginate/chitosan nanoparticles as a promising pulmonary carrier against Staphylococcus aureus.
Scolari IR; Páez PL; Musri MM; Petiti JP; Torres A; Granero GE
Drug Deliv Transl Res; 2020 Oct; 10(5):1403-1417. PubMed ID: 32363536
[TBL] [Abstract][Full Text] [Related]
5. Alternative Pharmaceutical Formulation for Oral Administration of Rifampicin.
Halicki PCB; Hädrich G; Boschero R; Ferreira LA; von Groll A; da Silva PEA; Dora CL; Ramos DF
Assay Drug Dev Technol; 2018 Dec; 16(8):456-461. PubMed ID: 30325673
[No Abstract] [Full Text] [Related]
6. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
[TBL] [Abstract][Full Text] [Related]
7. Gelatin nanocarriers as potential vectors for effective management of tuberculosis.
Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP
Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SC; Neto PJR; Ferreira D; Sarmento B; Reis S
Carbohydr Polym; 2021 Jan; 252():116978. PubMed ID: 33183580
[TBL] [Abstract][Full Text] [Related]
9. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
10. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.
Rani S; Gothwal A; Pandey PK; Chauhan DS; Pachouri PK; Gupta UD; Gupta U
Pharm Res; 2018 Dec; 36(1):19. PubMed ID: 30511238
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis.
Melo KJC; Henostroza MAB; Löbenberg R; Bou-Chacra NA
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110895. PubMed ID: 32409052
[TBL] [Abstract][Full Text] [Related]
12. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
13. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
14. Modified rifampin nanoparticles: Increased solubility with slow release Rate.
Farnia P; Velayati AA; Mollaei S; Ghanavi J
Int J Mycobacteriol; 2017; 6(2):171-176. PubMed ID: 28559520
[TBL] [Abstract][Full Text] [Related]
15. Interfacial Phenomenon Based Biocompatible Alginate-Chitosan Nanoparticles Containing Isoniazid and Pyrazinamide.
Kushwaha K; Dwivedi H
Pharm Nanotechnol; 2018; 6(3):209-217. PubMed ID: 29938624
[TBL] [Abstract][Full Text] [Related]
16. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
Singh H; Jindal S; Singh M; Sharma G; Kaur IP
Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin.
Lacerda L; Parize AL; Fávere V; Laranjeira MC; Stulzer HK
Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():161-7. PubMed ID: 24863212
[TBL] [Abstract][Full Text] [Related]
18. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.
Vieira ACC; Chaves LL; Pinheiro S; Pinto S; Pinheiro M; Lima SC; Ferreira D; Sarmento B; Reis S
Int J Pharm; 2018 Jan; 536(1):478-485. PubMed ID: 29203137
[TBL] [Abstract][Full Text] [Related]
19. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis.
Garg T; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):997-1001. PubMed ID: 25682840
[TBL] [Abstract][Full Text] [Related]
20. Application of Box-Behnken experimental design for the formulation and optimisation of selenomethionine-loaded chitosan nanoparticles coated with zein for oral delivery.
Vozza G; Danish M; Byrne HJ; Frías JM; Ryan SM
Int J Pharm; 2018 Nov; 551(1-2):257-269. PubMed ID: 30153488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
